^
Association details:
Biomarker:No biomarker
Cancer:Multiple Myeloma
Drug:carmustine (DNA synthesis inhibitor, Alkylating agent)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Source:
Published date:
05/16/2022
Excerpt:
Carmustine for Injection is a nitrosourea indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following...Multiple myeloma-in combination with prednisone…
Secondary therapy:
Chemotherapy